Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 3
2014 6
2015 8
2016 6
2017 13
2018 23
2019 20
2020 15
2021 15
2022 12
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Daher-Reyes GS, Merchan BM, Yee KWL. Daher-Reyes GS, et al. Expert Opin Investig Drugs. 2019 Oct;28(10):835-849. doi: 10.1080/13543784.2019.1667331. Epub 2019 Sep 19. Expert Opin Investig Drugs. 2019. PMID: 31510809 Review.
Areas covered: This article reviews the mechanism of action, pharmacology, safety profile and clinical efficacy of subcutaneous guadecitabine, a second-generation DNA methylation inhibitor in development for the treatment of AML and MDS. Expert opinion: Although guadeci …
Areas covered: This article reviews the mechanism of action, pharmacology, safety profile and clinical efficacy of subcutaneous guadecita …
Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin.
Kuang Y, El-Khoueiry A, Taverna P, Ljungman M, Neamati N. Kuang Y, et al. Mol Oncol. 2015 Nov;9(9):1799-814. doi: 10.1016/j.molonc.2015.06.002. Epub 2015 Jun 16. Mol Oncol. 2015. PMID: 26160429 Free PMC article.
Bromouridine-labeled RNA sequencing (Bru-seq) was employed to elucidate the effects of SGI-110 and/or oxaliplatin on genome-wide transcription. SGI-110 and the combination treatment inhibited the expression of genes involved in WNT/EGF/IGF signaling. . …
Bromouridine-labeled RNA sequencing (Bru-seq) was employed to elucidate the effects of SGI-110 and/or oxaliplatin on genome-wi …
SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome.
Tellez CS, Grimes MJ, Picchi MA, Liu Y, March TH, Reed MD, Oganesian A, Taverna P, Belinsky SA. Tellez CS, et al. Int J Cancer. 2014 Nov 1;135(9):2223-31. doi: 10.1002/ijc.28865. Epub 2014 Apr 5. Int J Cancer. 2014. PMID: 24668305 Free article.
SGI-110 caused widespread demethylation of more than 300 gene promoters and microarray analysis revealed expression changes for 212 and 592 genes with SGI-110 alone or in combination with entinostat. ...These preclinical in vivo findings demonstrate th …
SGI-110 caused widespread demethylation of more than 300 gene promoters and microarray analysis revealed expression changes fo …
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.
Papadatos-Pastos D, Yuan W, Pal A, Crespo M, Ferreira A, Gurel B, Prout T, Ameratunga M, Chénard-Poirier M, Curcean A, Bertan C, Baker C, Miranda S, Masrour N, Chen W, Pereira R, Figueiredo I, Morilla R, Jenkins B, Zachariou A, Riisnaes R, Parmar M, Turner A, Carreira S, Yap C, Brown R, Tunariu N, Banerji U, Lopez J, de Bono J, Minchom A. Papadatos-Pastos D, et al. J Immunother Cancer. 2022 Jun;10(6):e004495. doi: 10.1136/jitc-2022-004495. J Immunother Cancer. 2022. PMID: 35717027 Free PMC article. Clinical Trial.
We hypothesized that guadecitabine will overcome pembrolizumab resistance. METHODS: Patients received guadecitabine (45 mg/m(2) or 30 mg/m(2), administered subcutaneously on days 1-4), with pembrolizumab (200 mg administered intravenously starting from cycle 2 onwar …
We hypothesized that guadecitabine will overcome pembrolizumab resistance. METHODS: Patients received guadecitabine (45 mg/m(2 …
DNMT1: A key drug target in triple-negative breast cancer.
Wong KK. Wong KK. Semin Cancer Biol. 2021 Jul;72:198-213. doi: 10.1016/j.semcancer.2020.05.010. Epub 2020 May 24. Semin Cancer Biol. 2021. PMID: 32461152 Review.
This includes the hypomethylating agents azacitidine, decitabine and guadecitabine that might sensitize TNBC patients to immune checkpoint blockade therapy. ...
This includes the hypomethylating agents azacitidine, decitabine and guadecitabine that might sensitize TNBC patients to immune check …
Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways.
Dittmann J, Haydn T, Metzger P, Ward GA, Boerries M, Vogler M, Fulda S. Dittmann J, et al. Cell Death Differ. 2020 Jun;27(6):1878-1895. doi: 10.1038/s41418-019-0465-8. Epub 2019 Dec 12. Cell Death Differ. 2020. PMID: 31831875 Free PMC article.
Also, TNFalpha-blocking antibody Enbrel had little protective effect on SGI-110/ASTX660-induced cell death. Further, SGI-110 and ASTX660 acted in concert to promote cleavage of caspase-8 and BID, thereby providing a link between extrinsic and intrinsic …
Also, TNFalpha-blocking antibody Enbrel had little protective effect on SGI-110/ASTX660-induced cell death. Further, SGI …
Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.
Coral S, Parisi G, Nicolay HJ, Colizzi F, Danielli R, Fratta E, Covre A, Taverna P, Sigalotti L, Maio M. Coral S, et al. Cancer Immunol Immunother. 2013 Mar;62(3):605-14. doi: 10.1007/s00262-012-1365-7. Epub 2012 Nov 9. Cancer Immunol Immunother. 2013. PMID: 23138873
EXPERIMENTAL DESIGN: Cutaneous melanoma, mesothelioma, renal cell carcinoma, and sarcoma cells were treated in vitro with SGI-110. RT-PCR, quantitative RT-PCR, quantitative methylation-specific PCR, and flow cytometric analyses were performed to investigate changes …
EXPERIMENTAL DESIGN: Cutaneous melanoma, mesothelioma, renal cell carcinoma, and sarcoma cells were treated in vitro with SGI-110 …
SGI-110: DNA Methyltransferase Inhibitor Oncolytic.
Griffiths EA, Choy G, Redkar S, Taverna P, Azab M, Karpf AR. Griffiths EA, et al. Drugs Future. 2013 Aug;38(8):535-543. Drugs Future. 2013. PMID: 26190889 Free PMC article.
SGI-110 is a second-generation hypomethylating prodrug whose active metabolite is the well-characterized drug decitabine. ...
SGI-110 is a second-generation hypomethylating prodrug whose active metabolite is the well-characterized drug decitabine. ...
Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer.
Chen S, Xie P, Cowan M, Huang H, Cardenas H, Keathley R, Tanner EJ, Fleming GF, Moroney JW, Pant A, Akasha AM, Davuluri RV, Kocherginsky M, Zhang B, Matei D. Chen S, et al. J Clin Invest. 2022 Jul 15;132(14):e158800. doi: 10.1172/JCI158800. J Clin Invest. 2022. PMID: 35671108 Free PMC article. Clinical Trial.
To augment their activity, we used priming with the hypomethylating agent guadecitabine in a phase II study.MethodsEligible patients had platinum-resistant OC, normal organ function, measurable disease, and received up to 5 prior regimens. The treatment included guadeci …
To augment their activity, we used priming with the hypomethylating agent guadecitabine in a phase II study.MethodsEligible patients …
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
Wong J, Gruber E, Maher B, Waltham M, Sabouri-Thompson Z, Jong I, Luong Q, Levy S, Kumar B, Brasacchio D, Jia W, So J, Skinner H, Lewis A, Hogg SJ, Vervoort S, DiCorleto C, Uhe M, Gamgee J, Opat S, Gregory GP, Polekhina G, Reynolds J, Hawkes EA, Kailainathan G, Gasiorowski R, Kats LM, Shortt J. Wong J, et al. Leukemia. 2022 Jun;36(6):1654-1665. doi: 10.1038/s41375-022-01571-8. Epub 2022 Apr 22. Leukemia. 2022. PMID: 35459873 Free PMC article. Clinical Trial.
Response rates to azacitidine in PTCL of follicular helper cell origin are promising. Guadecitabine is a decitabine analogue with efficacy in MDS. In this phase II, single-arm trial, PTCL patients received guadecitabine on days 1-5 of 28-day cycles. ...Deletion of t …
Response rates to azacitidine in PTCL of follicular helper cell origin are promising. Guadecitabine is a decitabine analogue with eff …
121 results